IBI112 for teens with moderate to severe plaque psoriasis
Part of Skin clinical trials.
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old.
- You have had plaque psoriasis for at least 6 months.
- Your psoriasis is severe enough that your doctor has recommended light therapy or systemic (pill/injection) treatment.
- You have not taken a biologic medicine targeting IL-17 in the last 6 months or targeting TNF-alpha in the last 3 months.
- You do not have other forms of psoriasis (like pustular or guttate) or serious uncontrolled health problems.
- You have not used certain psoriasis creams or systemic treatments within specific timeframes before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial tests an oral medication called HS-10374 for people with mild to moderate plaque psoriasis who haven't gotten enough relief from topical treatments. The study will check if the drug is safe and effective at clearing psoriasis patches.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests how safe and how the body handles (pharmacokinetics) a psoriasis lotion called IDP-122 when used in children with plaque psoriasis. You may be able to join if your child has a suitable amount of plaque psoriasis and can follow safety rules during the study.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.